SCHEMBL11124804

SCHEMBL11124804

O=C(O)/C=C/c1cccc(C(=O)/C=C/c2ccccc2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.70
CYP1B1 Q16678 3/20 0.70
MAPT P10636 3/20 0.70
BCHE P06276 2/20 0.70
PLIN1 O60240 1/20 0.70
LMNA P02545 1/20 0.70
TNFRSF1A P19438 1/20 0.70
ACHE P22303 1/20 0.70
RECQL P46063 1/20 0.70
PLIN5 Q00G26 1/20 0.70
ABHD5 Q8WTS1 1/20 0.70
HDAC3 O15379 2/20 0.66
HDAC4 P56524 2/20 0.66
HDAC1 Q13547 2/20 0.66
HDAC7 Q8WUI4 2/20 0.66
HDAC2 Q92769 2/20 0.66
HDAC10 Q969S8 2/20 0.66
HDAC11 Q96DB2 2/20 0.66
HDAC8 Q9BY41 2/20 0.66
HDAC6 Q9UBN7 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11124806 1.00 MAOB (0.70) MAOBCYP1B1MAPTBCHEPLIN1
SCHEMBL6369083 0.91 MAOB (0.72) MAOBCYP1B1MAPTBCHEPLIN1
SCHEMBL16226002 0.91 MAOB (0.72) MAOBCYP1B1MAPTBCHEPLIN1
SCHEMBL30383945 0.91 MAOB (0.72) MAOBCYP1B1MAPTBCHEPLIN1
SCHEMBL11185107 0.89 MAOB (0.69) MAOBCYP1B1MAPTBCHEPLIN1
SCHEMBL11185094 0.89 MAOB (0.69) MAOBCYP1B1MAPTBCHEPLIN1
Chalcone SCHEMBL4385453 0.89 CYP1B1 (0.88) MAOBCYP1B1MAPTBCHEPLIN1
Chalcone SCHEMBL4385450 0.89 CYP1B1 (0.88) MAOBCYP1B1MAPTBCHEPLIN1
SCHEMBL13203405 0.89 CYP1B1 (0.81) MAOBCYP1B1MAPTBCHEPLIN1
SCHEMBL25214545 0.85 CYP1B1 (0.81) MAOBCYP1B1MAPTBCHEPLIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4421927-A SKIN DISORDERS SOCIETE DE RECHERCHES INDUSTRIELLES (S.O.R.I.) (FR) 1983-12-20 US claimed
EP-0051514-B1 CINNAMOYL-CINNAMIC ACID DERIVATIVE, ITS PREPARATION AND ITS USE AS A THERAPEUTIC AGENT SOCIETE DE RECHERCHES INDUSTRIELLES S.O.R.I. Société anonyme dite: (FR) 1983-11-23 EP claimed
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER THE GENERAL HOSPITAL CORPORATION (US) 2014-11-13 US disclosed
US-4421927-A SKIN DISORDERS SOCIETE DE RECHERCHES INDUSTRIELLES (S.O.R.I.) (FR) 1983-12-20 US disclosed
US-4421927-A SKIN DISORDERS SOCIETE DE RECHERCHES INDUSTRIELLES (S.O.R.I.) (FR) 1983-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER IL2RA, CD74, IL2 MAOB 3038/4885CYP1B1 2200/4885MAPT 3619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.